Summary
Signal counts
Assets tracked: 8
Watchlist assets: 7
Registry stop assets: 2
Sponsor overview
Dana-Farber Cancer Institute
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT00085397 | https://clinicaltrials.gov/study/NCT02028988 | https://clinicaltrials.gov/study/NCT04584255 | https://clinicaltrials.gov/study/NCT02040857 | https://clinicaltrials.gov/study/NCT02806648 | https://clinicaltrials.gov/study/NCT03065621 | https://clinicaltrials.gov/study/NCT04318223 | https://clinicaltrials.gov/study/NCT04569747 | https://clinicaltrials.gov/study/NCT00165230 | https://clinicaltrials.gov/study/NCT04071756 | https://clinicaltrials.gov/study/NCT04406272
Assets
Linked programs
- autologous dendritic cell-tumor fusion vaccine: Watchlist Signal (3/5)
- Enzalutamide: Low Signal (1/5)
- Niraparib: Watchlist Signal (2/5)
- Palbociclib: Timeline Staleness Signal (5/5)
- Pertuzumab+TRASTUZUMAB: Watchlist Signal (2/5)
- Thalidomide: Results Not Found Signal (2/5)
- Topical Tazarotene: Registry Stop Signal (3/5)
- VB11: Registry Stop Signal (4/5)